Document Detail


Ease of use and preference of a new versus widely available prefilled insulin pen assessed by people with diabetes, physicians and nurses.
MedLine Citation:
PMID:  21905942     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: FlexTouch® (FT; Novo Nordisk A/S, Bagsvaerd, Denmark) is a new prefilled insulin pen that has no push-button extension and low injection force. This multi-centre, crossover usability study evaluated the perceptions of, and preference for, FT versus another widely used prefilled pen, SoloStar® (SS; Sanofi, Paris, France), by people with diabetes and healthcare professionals.
RESEARCH DESIGN AND METHODS: Following instruction, participants performed injections into a foam cushion, randomly alternating between doses of 20, 40 and 80 international units (IU). Participants then answered questions on usability and preference.
RESULTS: In all, 59 people with diabetes and 61 healthcare professionals (30 physicians and 31 nurses) took part. Overall, significantly more respondents preferred to use FT than SS (83 vs 10%, respectively), found FT easier to use (83 vs 9%) and would recommend FT to others (83 vs 8%; p < 0.001 for all). More respondents found it 'very/fairly easy' to reach the push-button and to inject 20, 40 and 80 IU with FT (93, 90 and 88% to inject, respectively) than with SS (73, 43 and 15% to inject, respectively; p < 0.001 for all). Most respondents chose FT as giving them the most confidence in correct and complete insulin delivery (76 vs 6%; p < 0.001) and considerably more were 'very/rather confident' in managing their daily insulin injections with FT than with SS (88 vs 58%).
CONCLUSIONS: Most participants rated FT as easier to use and to inject with, were more confident in its accuracy of insulin delivery and preferred it to SS.
Authors:
David Oyer; Parth Narendran; Marianne Qvist; Marcus Niemeyer; Daniel A Nadeau
Publication Detail:
Type:  Controlled Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't     Date:  2011-09-12
Journal Detail:
Title:  Expert opinion on drug delivery     Volume:  8     ISSN:  1744-7593     ISO Abbreviation:  Expert Opin Drug Deliv     Publication Date:  2011 Oct 
Date Detail:
Created Date:  2011-09-21     Completed Date:  2012-01-26     Revised Date:  2012-03-06    
Medline Journal Info:
Nlm Unique ID:  101228421     Medline TA:  Expert Opin Drug Deliv     Country:  England    
Other Details:
Languages:  eng     Pagination:  1259-69     Citation Subset:  IM    
Affiliation:
Northwestern University, Feinberg School of Medicine, 211 East Chicago Avenue, Suite 1050, Chicago, IL 60611, USA. d-oyer@northwestern.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Cross-Over Studies
Diabetes Mellitus, Type 1 / drug therapy
Diabetes Mellitus, Type 2 / drug therapy
Female
Humans
Hypoglycemic Agents / administration & dosage*,  therapeutic use
Injections, Subcutaneous
Insulin / administration & dosage*,  therapeutic use
Male
Middle Aged
Nurses
Patient Preference*
Physicians
Syringes
Young Adult
Chemical
Reg. No./Substance:
0/Hypoglycemic Agents; 0/Insulin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Thymidylate synthase inhibitors for non-small cell lung cancer.
Next Document:  Emerging drugs which target the renin-angiotensin-aldosterone system.